Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1995 May 6;310(6988):1169–1172. doi: 10.1136/bmj.310.6988.1169

Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial.

O J Bergmann 1, S Ellermann-Eriksen 1, S C Mogensen 1, J Ellegaard 1
PMCID: PMC2549556  PMID: 7767151

Abstract

OBJECTIVES--To evaluate (a) the prophylactic effect of the antiherpetic drug acyclovir on oral ulcers in patients with acute myeloid leukaemia receiving remission induction chemotherapy and thus (b), indirectly, the role of herpes simplex virus in the aetiology of these ulcers. DESIGN--Randomised, double blind, placebo controlled trial. SUBJECTS--74 herpes simplex virus seropositive patients aged 18-84. Thirty seven patients received acyclovir (800 mg by mouth daily) and 37 placebo. The patients were examined daily for 28 days. MAIN OUTCOME MEASURES--Occurrence of herpes labialis, intraoral ulcers, and acute necrotising ulcerative gingivitis. RESULTS--The two populations were comparable in age, sex, type of antineoplastic treatment, and history of herpes labialis. Acute oral infections occurred in 25 of the acyclovir treated patients and 36 of the placebo treated patients (relative risk 0.69 (95% confidence interval 0.55 to 0.87)). This difference was due to a reduction in the incidence of herpes labialis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)), intraoral ulcers excluding the soft palate (one case versus 13 cases; relative risk 0.08 (0.01 to 0.56)), and acute necrotising ulcerative gingivitis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)). However, ulcers on the soft palate were diagnosed with similar frequency in the two groups. Isolation of herpes simplex virus type 1 in saliva was reduced from 15 cases in the placebo group to one case in the acyclovir group (relative risk 0.07 (0.01 to 0.48)). CONCLUSION--Intraoral ulcers excluding the soft palate are most often due to infection with herpes simplex virus, whereas ulcers on the soft palate have a non-herpetic aetiology. The findings suggest that acute necrotising ulcerative gingivitis may also be due to herpes simplex virus. Prophylaxis with acyclovir should be considered for patients with acute myeloid leukaemia during remission induction therapy.

Full text

PDF
1169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergmann O. J., Ellegaard B., Dahl M., Ellegaard J. Gingival status during chemical plaque control with or without prior mechanical plaque removal in patients with acute myeloid leukaemia. J Clin Periodontol. 1992 Mar;19(3):169–173. doi: 10.1111/j.1600-051x.1992.tb00634.x. [DOI] [PubMed] [Google Scholar]
  2. Bergmann O. J., Ellermann-Eriksen S., Mogensen S. C., Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ. 1995 May 6;310(6988):1169–1172. doi: 10.1136/bmj.310.6988.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergmann O. J., Mogensen S. C., Ellegaard J. Herpes simplex virus and intraoral ulcers in immunocompromised patients with haematologic malignancies. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):184–190. doi: 10.1007/BF01963835. [DOI] [PubMed] [Google Scholar]
  4. Bergmann O. J. Oral infections and fever in immunocompromised patients with haematologic malignancies. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):207–213. doi: 10.1007/BF01965262. [DOI] [PubMed] [Google Scholar]
  5. Bergmann O. J. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol. 1988 Oct;26(10):2105–2109. doi: 10.1128/jcm.26.10.2105-2109.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bergmann O. J. Oral infections in haematological patients. Pathogenesis and clinical significance. Dan Med Bull. 1992 Feb;39(1):15–29. [PubMed] [Google Scholar]
  7. Gluckman E., Lotsberg J., Devergie A., Zhao X. M., Melo R., Gomez-Morales M., Nebout T., Mazeron M. C., Perol Y. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983 Sep 24;2(8352):706–708. doi: 10.1016/s0140-6736(83)92248-1. [DOI] [PubMed] [Google Scholar]
  8. Hann I. M., Prentice H. G., Blacklock H. A., Ross M. G., Brigden D., Rosling A. E., Burke C., Crawford D. H., Brumfitt W., Hoffbrand A. V. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):384–388. doi: 10.1136/bmj.287.6389.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnsen H. E., Bergmann O. J., Ellegaard J., Bastrup-Madsen P. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period. Dan Med Bull. 1989 Apr;36(2):189–193. [PubMed] [Google Scholar]
  10. Johnson B. D., Engel D. Acute necrotizing ulcerative gingivitis. A review of diagnosis, etiology and treatment. J Periodontol. 1986 Mar;57(3):141–150. doi: 10.1902/jop.1986.57.3.141. [DOI] [PubMed] [Google Scholar]
  11. Lundgren G., Wilczek H., Lönnqvist B., Lindholm A., Wahren B., Ringdén O. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl. 1985;47:137–144. [PubMed] [Google Scholar]
  12. Lönnqvist B., Palmblad J., Ljungman P., Grimfors G., Järnmark M., Lerner R., Nyström-Rosander C., Oberg G. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139–144. doi: 10.1007/BF00366060. [DOI] [PubMed] [Google Scholar]
  13. Morris J. A., Gardner M. J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) 1988 May 7;296(6632):1313–1316. doi: 10.1136/bmj.296.6632.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roed-Petersen B., Renstrup G. A topographical classification of the oral mucosa suitable for electronic data processing. Its application to 560 leukoplakias. Acta Odontol Scand. 1969 Dec;27(6):681–695. doi: 10.3109/00016356909026317. [DOI] [PubMed] [Google Scholar]
  15. Saral R., Ambinder R. F., Burns W. H., Angelopulos C. M., Griffin D. E., Burke P. J., Lietman P. S. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983 Dec;99(6):773–776. doi: 10.7326/0003-4819-99-6-773. [DOI] [PubMed] [Google Scholar]
  16. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  17. Wade J. C., Newton B., Flournoy N., Meyers J. D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984 Jun;100(6):823–828. doi: 10.7326/0003-4819-100-6-823. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES